Adagene (ADAG) Partners With Incyte (INCY) to Evaluate Combination Therapy for Colorectal Cancer [Yahoo! Finance]
Adagene Inc. - ADS, each representing 1.25 ordinary shares (ADAG)
Company Research
Source: Yahoo! Finance
Adagene Inc. (NASDAQ: ADAG ) is one of the unstoppable stocks that could double your money. On April 2, Adagene announced a clinical collaboration with Incyte Corp. (NASDAQ: INCY ) to evaluate a novel combination therapy for microsatellite stable colorectal cancer/MSS CRC. The study will combine Adagene's muzastotug/ADG126, which is a masked anti-CTLA-4 SAFEbody, with Incyte's INCA33890, a bispecific antibody targeting TGFßR2 and PD-1. This Phase 1 trial, expected to begin in 2026, will focus on third-line patients both with and without liver metastases, a group that typically faces a poor prognosis and limited response to standard immunotherapies. The collaboration uses muzastotug's potential as a backbone therapy, designed to increase the therapeutic index by selectively activating in the tumor microenvironment. While Incyte will sponsor and conduct the trial, Adagene will provide the clinical supply of muzastotug. Adagene (ADAG) Partners With Incyte (INCY) to Evaluate Combinat
Show less
Read more
Impact Snapshot
Event Time:
ADAG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADAG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADAG alerts
High impacting Adagene Inc. - ADS, each representing 1.25 ordinary shares news events
Weekly update
A roundup of the hottest topics
ADAG
News
- Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor TypesGlobeNewswire
- Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory BoardGlobeNewswire
- Adagene (ADAG) had its price target raised by Guggenheim from $9.00 to $10.00. They now have a "buy" rating on the stock.MarketBeat
- Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs [Yahoo! Finance]Yahoo! Finance
- Adagene announces pricing of $70M public offering of ADS [Seeking Alpha]Seeking Alpha
ADAG
Sec Filings
- 4/17/26 - Form 6-K
- 4/2/26 - Form 424B5
- 4/2/26 - Form 6-K
- ADAG's page on the SEC website